Cyclerion Therapeutics, Inc. (CYCN) News

Cyclerion Therapeutics, Inc. (CYCN): $2.69

0.41 (+17.98%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add CYCN to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#103 of 439

in industry

Filter CYCN News Items

CYCN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest CYCN News From Around the Web

Below are the latest news stories about CYCLERION THERAPEUTICS INC that investors may wish to consider to help them evaluate CYCN as an investment opportunity.

Cyclerion Appoints Regina Graul, Ph.D., as President

– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for

Yahoo | December 4, 2023

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G

Yahoo | November 30, 2023

Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With Losses

Insiders who bought US$1.95m worth of Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) stock at an average buy price of...

Yahoo | November 28, 2023

The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assets

Peter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK.

Yahoo | August 3, 2023

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement

Yahoo | July 31, 2023

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

CAMBRIDGE, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (“Cyclerion” or the “Company”) (Nasdaq: CYCN) today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Cyclerion has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Cyclerion is in compliance with all applicable listing standards. On June 1, 2022, Cyclerion was notified by Nasdaq that it was

Yahoo | June 1, 2023

Cyclerion Announces Reverse Stock Split

CAMBRIDGE, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (the “Company”, “Cyclerion Therapeutics”, “Cyclerion”) (Nasdaq: CYCN) announced today that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20, effective as of 5:00 p.m. Eastern Time on May 15, 2023. The reverse stock split was approved by the Company’s stockholders at its annual meeting of stockholders held on May 15, 2023, with the final ratio determined by the Comp

Yahoo | May 15, 2023

Cyclerion Therapeutics to Sell Assets for $81M, CEO Transition To New Spin-Off Private Company Established By Shareholders, New Investors

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has agreed to sell two of its assets - zagociguat (formerly CY6463) and CY3018, to a new private company ("NewCo") formed by certain current Cyclerion shareholders and new investors who have agreed to invest $81 million. Cyclerion will receive $8 million as reimbursement for all expenses related to zagociguat and CY3018 between the signing and closing of the transaction and 10% equity ownership in NewCo. Cyclerion will also have additional future equity

Yahoo | May 12, 2023

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

Certain Cyclerion shareholders and new investors have agreed to invest $81M to launch a new company targeting diseases of mitochondrial dysfunction Cyclerion to receive $8M in cash and 10% equity in the new company in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) announced today that it has signed a definitive

Yahoo | May 11, 2023

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Definitive agreement reached with new company (“NewCo”) established by certain Cyclerion shareholders and new investors Cyclerion to receive $8M in cash and 10% equity in NewCo in exchange for its zagociguat and CY3018 assets Definitive agreement signing triggers previously announced $5M equity investment in Cyclerion Cyclerion CEO Peter Hecht Ph.D. to lead NewCo while continuing to serve on the Cyclerion board as one of the company’s largest shareholders Biopharma executive Errol De Souza Ph.D.

Yahoo | May 11, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!